39 results on '"Stilgenbauer, Stephan"'
Search Results
2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
3. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
4. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
5. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
6. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
7. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
8. EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
9. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
10. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia
11. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas
12. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
13. COVID-19 among fit patients with CLL treated with venetoclax-based combinations
14. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
15. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
16. Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells
17. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
18. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL
19. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
20. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia
21. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
22. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
23. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
24. ERIC recommendations for TP53mutation analysis in chronic lymphocytic leukemia—2024 update
25. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
26. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
27. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
28. Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells
29. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Mycgain predicting poor outcome in patients
30. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
31. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
32. Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL
33. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
34. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia
35. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+T cells in chronic lymphocytic leukemia
36. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
37. EOMES is essential for antitumor activity of CD8+T cells in chronic lymphocytic leukemia
38. Control of chronic lymphocytic leukemia development by clonally-expanded CD8+T-cells that undergo functional exhaustion in secondary lymphoid tissues
39. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.